Subhashis Banerjee

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Craig L. Leonardi, Robert Matheson, Claus Zachariae et al. · New England Journal of Medicine · 2012 · 930 citations · Full text

Medicine, Dermatology, Immunology +17

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Kim Papp, Kenneth B. Gordon, Diamant Thaçi et al. · New England Journal of Medicine · 2018 · 414 citations · Full text

Life Sciences, Dermatology, Pharmacology +17

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W. Armstrong, Melinda Gooderham, Richard B. Warren et al. · Journal of the American Academy of Dermatology · 2022 · 347 citations · Full text

Medicine, Dermatology, Pharmacotherapy +7

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober, Diamant Thaçi, Howard Sofen et al. · Journal of the American Academy of Dermatology · 2022 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16